Assessment of impact of peripheral blood immune measures and radiation-induced lymphopenia on outcomes in Non-small cell lung cancer patients treated with concurrent chemoradiation (cCRT) and immune check point inhibition
Latest Information Update: 06 May 2022
At a glance
- Drugs Antineoplastics (Primary) ; Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 06 May 2022 New trial record